Neurology and Neurological Rehabilitation at Fondazione Santa Lucia

Clinical research here focuses on nervous system diseases, especially Parkinson’s disease and Alzheimer’s disease, with studies aimed at understanding symptoms, tracking progression, and evaluating new treatment options that may improve daily function and quality of life.

  • Studies in Parkinson’s disease are exploring the safety, tolerability, and potential benefits of new therapies designed to better manage motor symptoms and treatment-related fluctuations.
  • Research in Alzheimer’s disease and mild cognitive impairment is assessing whether emerging treatments can help slow cognitive decline and support memory and function in earlier stages of disease.
  • The site is also involved in trials for major depressive disorder, examining approaches that may improve response in people whose symptoms have not fully improved with standard antidepressant care.

Overall, the studies at this Rome research site aim to advance both symptom control and longer-term disease management across neurology and psychiatry.

Mental Health Research in Psychiatry and Psychology

The trial portfolio includes work in mental disorders, with a particular focus on major depressive disorder. These studies are designed to test whether new or repurposed treatments can offer added benefit for people who continue to experience depressive symptoms despite ongoing antidepressant therapy.

  • Research in major depressive disorder is evaluating whether investigational treatments can improve mood symptoms and overall treatment response.
  • The objective of these studies is to compare new approaches with placebo and determine whether they may provide meaningful support as add-on therapy.

This area of research complements the site’s broader neurological rehabilitation expertise by addressing conditions that affect both emotional well-being and everyday functioning.

Alzheimer's Disease Research

A major part of the clinical trial activity at Fondazione Santa Lucia centers on Alzheimer’s disease, including early symptomatic Alzheimer’s disease, prodromal disease, and mild cognitive impairment linked to Alzheimer’s. The studies are intended to test new therapies that may help preserve cognition and daily function for as long as possible.

  • Trials in early Alzheimer’s disease are examining whether investigational treatments can slow cognitive and functional decline.
  • Research in mild cognitive impairment and mild dementia due to Alzheimer’s is focused on measuring changes in memory, thinking, and everyday abilities.
  • These studies aim to improve understanding of disease progression while evaluating potential disease-modifying therapies.

Together, these projects reflect a strong commitment to advancing care for people in the earlier stages of neurodegenerative disease.

Neurodegenerative Treatment Development

The site is also contributing to broader efforts in neurodegenerative disease research by studying investigational medicines that may affect the course of Alzheimer’s disease and Parkinson’s disease. The purpose of this work is to evaluate both safety and effectiveness while supporting the development of more targeted treatment strategies.

  • Studies are assessing new therapies that may help reduce symptoms or slow worsening in chronic brain disorders.
  • Research includes evaluation of treatment effectiveness alongside careful monitoring of tolerability and patient benefit.

With expertise in neurology and rehabilitation, the site contributes to clinical research aimed at improving long-term outcomes for patients living with complex brain disorders.